Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2016 pubmed 56 citations

Ghrelin induces colon cancer cell proliferation through the GHS-R, Ras, PI3K, Akt, and mTOR signaling pathways.

Lien. Gi-Shih GS; Lin. Chien-Huang CH; Yang. You-Lan YL; Wu. Ming-Shun MS; Chen. Bing-Chang BC

Key Findings

  • Ghrelin stimulates proliferation of HT‑29 colon cancer cells via the GHS‑R receptor.
  • Inhibiting GHS‑R with [D‑Lys3]‑GHRP‑6 reduces ghrelin‑induced cancer cell growth.
  • Blocking Ras, PI3K, Akt, or mTOR each diminishes the proliferative effect, confirming the pathway’s role.

Practical Outcomes

  • For biohackers using GHRP‑6 to boost growth hormone, this suggests a potential risk of promoting colon cancer cell growth if the pathway is active. It highlights the importance of monitoring gut health and possibly limiting chronic GHRP‑6 use, especially in individuals with a history of colon issues. Consider using the lowest effective dose and incorporating regular medical screening.

Summary

The study shows that ghrelin, a hormone that GHRP‑6 mimics, can make colon cancer cells grow faster by activating a chain of signals (GHS‑R → Ras → PI3K → Akt → mTOR). Blocking the ghrelin receptor with a compound called [D‑Lys3]‑GHRP‑6 or inhibiting any step in that chain slows the cancer cell growth.

Abstract

Colon cancer is the third most common malignancy worldwide. Recently, some interesting associations between ghrelin and cancer were reported, and it may participate in colon cancer development. In the present report, we explored the role of the growth hormone secretagogue receptor (GHS-R), Ras, phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR) pathways in the ghrelin-induced proliferation of human colon cancer cells. Ghrelin-caused HT-29 proliferation was reduced by [D-Lys3]-GHRP-6 (a GHS-R inhibitor). We also found that a dominant negative mutant of Ras (Ras DN), a PI3K inhibitor (LY 294002), an Akt DN, and an mTOR inhibitor (rapamycin) attenuated ghrelin-caused colon cancer cell proliferation. We found that ghrelin induced time-dependent increases in Ras activity. Moreover, ghrelin-mediated Akt Ser473 phosphorylation was attenuated by a Ras DN and LY 294002. Furthermore, a Ras DN, LY 294002, and an Akt DN all inhibited ghrelin-caused mTOR Ser2448 phosphorylation. These results indicate that the Ras/PI3K/Akt/mTOR cascade plays a critical role in ghrelin-induced colon cancer cell proliferation.

Study Information

Provider

pubmed

Year

2016

Date

2016-02-12T00:00:00.000Z

DOI

10.1016/j.ejphar.2016.02.044

Citations

56

References

43